Your browser doesn't support javascript.
loading
A Preliminary Controlled Trial of Endoscopic Ultrasound-guided Fiducial Markers to Guide Pancreas Surgery.
Chang, Patrick W; Sadik, Jonathan; Sahakian, Ara B; Kankotia, Ravi; Ko, Christopher; Serna, Jessica; Rodriguez, Alex; Lee, Helen; Kulkarni, Sujit; Genyk, Yuri; Sheikh, Mohd; Buxbaum, James L.
Afiliação
  • Chang PW; Department of Internal Medicine, Division of Gastroenterology.
  • Sadik J; Department of Internal Medicine, Division of Gastroenterology.
  • Sahakian AB; Department of Internal Medicine, Division of Gastroenterology.
  • Kankotia R; Department of Internal Medicine, Division of Gastroenterology.
  • Ko C; Department of Internal Medicine, Division of Gastroenterology.
  • Serna J; Department of Internal Medicine, Division of Gastroenterology.
  • Rodriguez A; Department of Internal Medicine, Division of Gastroenterology.
  • Lee H; Department of Internal Medicine, Division of Gastroenterology.
  • Kulkarni S; Department of Surgery, Division of Hepatobiliary, Pancreas and Abdominal Transplant Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Genyk Y; Department of Surgery, Division of Hepatobiliary, Pancreas and Abdominal Transplant Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Sheikh M; Department of Surgery, Division of Hepatobiliary, Pancreas and Abdominal Transplant Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Buxbaum JL; Department of Internal Medicine, Division of Gastroenterology.
J Clin Gastroenterol ; 2023 Dec 19.
Article em En | MEDLINE | ID: mdl-38112649
ABSTRACT

OBJECTIVE:

Endoscopic ultrasound (EUS) is routinely used for fiducial marker placement (FMP) to guide stereotactic radiation of pancreatic tumors, but EUS-FMP explicitly to guide surgery has not been studied in a prospective, controlled manner. Multipurpose EUS systems have been developed that facilitate simultaneous EUS-FMP at the time of biopsy. We aimed to evaluate the feasibility of EUS-FMP to guide pancreatic resection.

METHODS:

In this prospective trial, we enrolled patients with resectable pancreas masses undergoing tissue sampling and placed preloaded fiducials immediately after biopsy. Intraprocedure confirmation of carcinoma, neuroendocrine, and nonlymphomatous neoplasia by rapid on-site evaluation and lesion size <4 cm was required. The main outcomes were the feasibility and ease of preoperative placement and intraoperative detection of the markers using predefined Likert scales.

RESULTS:

In 20 patients, EUS-FMP was successful before planned surgery and placement was technically straightforward (Likert Scale 9.1 ± 1.3; range 1, most challenging to 10, most facile). Intraoperative detection was feasible and improved when compared with a pre-established comparator of 5 representing an equivalent lesion without a marker (Likert Scale 7.8 ± 2.2; range 1, most difficult to 10, most facile; P = 0.011). The mean tumor size on EUS was 1.7 ± 0.9 (range 0.5 to 3.6) cm.

CONCLUSION:

EUS-FMP is feasible and safe for resectable pancreatic tumors before surgery and may assist in perioperative detection. Preloaded fiducials may be considered for placement at the time of initial referral for EUS-fine needle biopsy.

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: J Clin Gastroenterol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Idioma: En Revista: J Clin Gastroenterol Ano de publicação: 2023 Tipo de documento: Article